GlassScriptPhysician profile
Gregory L Lassiter
NPI 1912984758
$502.44
in general payments reported to CMS, 2019-2025
15 companies · $475 in 2025
The $475 reported for 2025 was more than what 79% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $27.70 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $502.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $82.49 | 2025 | Calquence |
| Merck Sharp & Dohme LLC | $57.30 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Legend Biotech USA INC. | $55.96 | 2025 | Carvykti |
| Janssen Biotech, INC. | $51.08 | 2025 | Darzalex, Tecvayli, Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $34.73 | 2025 | Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $27.70 | 2024 | |
| Iovance Biotherapeutics, INC. | $26.77 | 2025 | Amtagvi |
| Cycle Pharmaceuticals INC | $23.32 | 2025 | Phyrago |
| Incyte Corporation | $22.44 | 2025 | Jakafi |
| Shield Therapeutics INC | $22.28 | 2025 | |
| Syndax Pharmaceuticals, INC. | $22.09 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.16 | 2025 | |
| Sumitomo Pharma America, INC. | $19.35 | 2025 | Orgovyx |
| Acrotech Biopharma INC. | $18.32 | 2025 | Beleodaq |
| Genzyme Corporation | $17.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lassiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.